Table 1.
Cancer type | Cell lines | Molecular target | Effect | References |
---|---|---|---|---|
Acute myeloid leukemia | In vitro in MV4;11, MOLM13 and NOMO1 cell lines. In vivo in mice. | Inhibit BCL2, C-MYC and CDK6. | Cause G0/G1 arrest and induce cell apoptosis | (7) |
Acute myeloid leukemia | In vitro SEM, RS4; 11 and ALL-PO cell lines. In vivo in mice. | Inhibit HOXA7/9 and RUNX1. | Inhibit proliferation, cause G0/G1 arrest, block cell division and induce cell apoptosis. | (36) |
Acute myeloid leukemia | In vitro in MOLM13 and THP1 cell lines. In vivo in humanized bone marrow xenograft model of secondary MLL-AF9-driven B-ALL. | Inhibit Bax, BCL2 and C-MYC. Upregulate CDKN1A and CDKN1B. | Inhibit proliferation, cause G0/G1 arrest and induce cell apoptosis. | (37) |
Acute myeloid leukemia | In vitro in OCI-AML3, KG-1, SKM1, Kasumi, ME-1 cell lines. In vivo in mice. | Inhibit BCL2, C-MYC and IRF8. | Cause cell cycle arrest and induce cell apoptosis. | (38) |
Acute myeloid leukemia | In vitro in AML lines with dual DNMT3AR882H and RAS mutations. In vivo in mice. | Inhibit Mn1, Mycn and Bcl2. | Cause cell cycle arrest and induce cell apoptosis. | (39) |
Acute myeloid leukemia | In vitro in U937, HL-60, R-U937 and R-HL-60 cell lines. | Inhibit HP1γ. | Inhibit proliferation. | (40) |
Myeloma | In vitro in H929, KMS12PE, KMS12BM, KMS18, KMS11 and RPMI8226 cell lines. In vivo in mice. | Downregulate MYC. Upregulate HEXIM1. | Cause cell cycle arrest and induce cell apoptosis. | (41) |
Myeloma | In vitro in U266, RPMI8226, MM1 and KMS11 cell lines. | Inhibit MYCL1 in U266. Inhibit c-MYC in RPMI8226, MM1 and KMS11. | Inhibit proliferation and cause cell cycle arrest. | (42) |
Myeloma | In vitro in SKO-007(J3), CD138+ multiple myeloma cells and NK cells isolated from the bone marrow of multiple myeloma patients. | Inhibit IRF4 and upregulate MICA. | Promote NK cell degranulation. | (29) |
Myeloma | In vitro in RAW 264.7 cell lines and in mononuclear cells isolated from healthy donors and patients with multiple myeloma. | Inhibit TRACP, MMP9, Ctsk and c-Src. Upregulate OPG. Suppress IκB-α degradation and p65 nuclear translocation. | Inhibit osteoclast formation and inflammatory cytokine secretion. | (11) |
Primary effusion lymphoma | In vitro in BC1, BC3 and BCBL1 cell lines. In vivo in mice. | Inhibit c-Myc. | Inhibit proliferation and cause G0/G1 arrest. | (43) |
Mantle cell lymphoma | In vitro in JVM-2, MINO, Z138 and KPUM-YY1 cell lines | Inhibit PAX5, IKZF1, BTK, SYK, EBF1 and MYC. | Cause G1/S arrest and induce cell apoptosis. | (44) |
Myeloproliferative neoplasms | In vitro in a human erythroleukemic cell line. | Inhibit LMO2. | Inhibit proliferation and induce cell apoptosis. | (45) |
Triple-negative breast cancer | In vitro in MDA-MB-231, MDA-MB-468 and BT549 cell lines. | Inhibit IKBKE. | Inhibit proliferation and induce cell apoptosis. | (12) |
Breast cancer | In vitro in MB-231, MB-468 and SK-BR-3 cell lines. | Upregulate GSSG and MDA levels. | Induce ferroptosis. | (46) |
Breast cancer | In vivo in mice implanted with Mvt1 and 6DT1. | Inhibit proliferation. | (47) | |
Glioma | In vitro in U87MG, A172, SW1783 cell lines and glioblastoma stem cells derived from patients. In vivo in mice. | Inhibit proliferation and cause G1/S arrest. | (48) | |
Glioma | In vitro in U87MG, A172, LN18, T98G cell lines and in patient derived xenograft cells. | Inhibit HOTAIR, TUG1 and H19. | Inhibit proliferation. | (49) |
Glioma | In vitro in U87MG, U251 cell lines and Primary cells obtained from GBM patients. In vivo in mice. | Inhibit Notch1/NICD/Hes1. | Reduce self‐renewal and proliferation of glioma-initiating cells. | (6) |
Melanoma | In vitro in Me1007, SK-Mel-28, Mel-RMu, Mel-JD, Mel-RM and the resistant (post) cell lines from patients. In vivo in mice. | Inhibit p50, p105 and CDK6. Upregulate of CDKN1A. | Inhibit cytokine/chemokine production, cause cell cycle arrest and induce cell apoptosis. | (4) |
Melanoma | In vitro in Mel-RMU, Sk-Mel-28, Mel-RM, Mel-JD and Me1007 cell lines. In vivo in mice. | Inhibit XIAP. Upregulate of BIM and p21. | Cause cell cycle arrest and induce cell apoptosis. | (50) |
Neuroblastoma | In vitro in SK-N-BE (2) and Kelly cell lines. | Inhibit NCYM and N-Myc. Upregulate of TP53INP1. | Induce cell apoptosis. | (51, 52) |
Ovarian cancer | In vitro in 28 ovarian cancer cell lines. In vivo in mice. | Inhibit FoxM1, AURKB, survivin, cyclinB and PLK1. | Inhibit proliferation, cause G0/G1 arrest. | (5) |
Ovarian cancer |
In vitro in SK-OV-3, CaoV-3 and ID8 cell lines. In vivo in mice. |
Upregulate BIM and Cleaved caspase-3. Inhibit MMP2, MMP9 and p-Stat3. | Inhibit proliferation, invasion and migration, induce cell apoptosis and antitumor immune response. | (30) |
Ovarian cancer | In vitro in A2780CP, OVCAR3 and SKOV3 cell lines. | Inhibit FoxM1, AURKB, cyclinB1, ZEB2, N-cadherin, Survivin and Bcl-2. | Inhibit proliferation, invasion, migration and induce cell apoptosis. | (53) |
Colorectal cancer | In vitro in HCT116 transduced with SLUG or SNAIL retroviruses. | Suppress EMT and inhibit SP cell production. | (54) | |
Castration-resistant prostate cancer | In vitro in LNCaP95 and VCaP cell lines. | Inhibit AR-V7, C-MYC, PSA and TMPRSS2. | Inhibit proliferation and AR signaling. | (55) |
Pancreatic ductal adenocarcinoma | In vitro in human primary pancreatic stellate cells. | Inhibit COL1A1, COL1A2 and collagen I. | Attenuate fibrosis. | (56) |
Non-small cell lung carcinoma | In vitro in Calu-1, H460 and A549 cell lines. | Inhibit c-Myc, eIF4E and cyclin D1. | Inhibit proliferation. | (57) |